1. Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future;Jimenez-Yuste;Blood Transfus.,2014
2. Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates;Mancuso;J. Clin. Med.,2017
3. European Medicines Agency, Summary of Product Characteristics (ELOCTA). [cited 2020a June]; Available from: 〈https://www.ema.europa.eu/en/documents/product-information/elocta-epar-product-information_en.pdf〉.
4. European Medicines Agency, Summary of Product Characteristics (Jivi). [cited 2020b June]; Available from: 〈https://www.ema.europa.eu/en/documents/product-information/jivi-epar-product-information_en.pdf〉.
5. European Medicines Agency, Summary of Product Characteristics (Adynovate). [cited 2020c June]; Available from: 〈https://www.ema.europa.eu/en/documents/product-information/adynovi-epar-product-information_en.pdf〉.